Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056654 · ClinicalTrials.gov registry record · NA
Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer
A NA study, sponsored by Abbott.
- Completed
- Registry status
- NA
- Development phase
- 164
- Enrollment target
NCT00056654: Completed NA study, sponsored by Abbott.
NCT00056654 is a NA study that has completed, run by Abbott. The registered enrollment target is 164 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00056654, a NA study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- NA
- Development phase
- 164 participants
- Enrollment target
Study Summary
The primary purpose of the study is to determine if a new sustained-release 45 mg (depot) formulation of leuprolide acetate will reduce serum testosterone levels to and maintain them at medically castrate levels in subjects with prostatic adenocarcinoma.
Interventions
- DRUG Leuprolide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2003-03 |
| Est. Completion | 2004-07 |
| Phase | NA |
What the finished NCT00056654 record still lists
NCT00056654 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which Leuprolide acetate is the first listed.
NCT00056654 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00056654 about?
NCT00056654 is a clinical study titled "Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer". The primary purpose of the study is to determine if a new sustained-release 45 mg (depot) formulation of leuprolide acetate will reduce serum testosterone levels to and maintain them at medically castrate levels in subjects with prostatic adenocarcinoma.
What is the current status of trial NCT00056654?
This trial is currently completed. It is a NA study. The enrollment target is 164 participants. The study started on 2003-03. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00056654?
The interventions under investigation include: Leuprolide acetate (DRUG).
Who is sponsoring clinical trial NCT00056654?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00056654's enrollment target sits among peer trials
164 626th of 2000 higher than 1,374 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia